Press Releases

Shine Medical Technologies Logo

SHINE holds 2nd 2015 Community Meeting

December 7, 2015 – SHINE invites the Janesville community to an update on the development of its medical isotope production facility. Since our last meeting in June, SHINE’s primary regulator, the Nuclear Regulatory Commission, has completed their safety and environmental reviews and recommended the approval of a Construction Permit for the SHINE facility.

Shine Medical Technologies Logo

SHINE Achieves Major Milestone on Path to Construction Permit Approval

October 26, 2015 – SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements, announced today that the staff of its primary regulator, the Nuclear Regulatory Commission (NRC), has completed their safety and environmental reviews and recommends approval of a Construction Permit for the SHINE facility.

srnlimage

SHINE Signs License Agreement for SRNL Innovation

October 14, 2015 – Savannah River Nuclear Solutions, LLC (SRNS), the management and operating contractor for the U.S. Department of Energy’s Savannah River National Laboratory (SRNL), has granted SHINE Medical Technologies, Inc. (SHINE) an exclusive license on SRNL’s patented hydrogen isotope separation process for use in medical isotope production.

toddbiopic

Todd Asmuth Joins SHINE Medical Technologies Team

October 1, 2015 – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that Todd Asmuth will join the company as President, reporting to the CEO and focusing on investor and customer relations. The appointment comes as the company prepares to bring its first product to market, molybdenum-99 (moly-99).

jeffdphoto

NSF Award Helps SHINE Accelerate Efforts to Become a Major Domestic Producer of Iodine-131

June 30, 2015 – SHINE Medical Technologies, a Wisconsin-based medical isotope company, announced today that it has been awarded $150,000 from the National Science Foundation for Phase I of an SBIR (Small Business Innovation Research) Grant. This grant will fast-track SHINE’s ongoing development of iodine-131 extraction and purification processes, which SHINE may decide to pursue at its medical isotope production facility.

press-release-photo

Argonne National Laboratory Demonstration of SHINE Process Produces Commercial-Grade Medical Isotopes

June 15, 2015 – Argonne National Laboratory (Argonne) and SHINE Medical Technologies, Inc. announced today that Argonne successfully demonstrated the production, separation and purification of molybdenum-99 (Mo-99) from SHINE’s innovative liquid target. The resulting Mo-99 product purity was equivalent to the Mo-99 used in the supply chain today. The demonstration—known as Mini-SHINE— uses the same process flows that will be used in the SHINE manufacturing facility and further validates SHINE’s technical approach.

NRC-Logo

Nuclear Regulatory Commission Issues Draft Environmental Impact Statement for SHINE Facility

May 21, 2015 – SHINE Medical Technologies, a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, announced today that the Company’s primary regulator, the Nuclear Regulatory Commission (NRC), has released for public review and comment the draft Environmental Impact Statement (EIS) for the SHINE medical isotope production facility in Janesville, WI.